An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus

Lupus

Volumn 18, Issue 6, 2009, Pages 547-555

  Pena Rossi, Claudia ^a   Nasonov, E ^b   Stanislav, M ^b   Yakusevich, V ^c   Ershova, O ^c   Lomareva, N ^d   Saunders, H ^a   Hill, J ^e   Nestorov, I ^e  

^a MERCK SERONO S A   (Switzerland)

^b V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

^c Solovievs Clinical Hospital for Urgent Medical Care   (Russian Federation)

^d City Clinical Hospital No 25   (Russian Federation)

^e ZymoGenetics Inc   (United States)

Author keywords

APRIL; Atacicept; Biological agents; BLyS; Systemic lupus erythematosus; TACI Ig

Indexed keywords

ATACICEPT; IMMUNOGLOBULIN; PLACEBO;

ADULT; AGED; ALLERGIC BLEPHARITIS; ALLERGIC CONJUNCTIVITIS; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG ELIMINATION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY DISORDER; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; LEUKOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ABSCESS; SYSTEMIC LUPUS ERYTHEMATOSUS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VIRAL RESPIRATORY TRACT INFECTION;

ADULT; AGED; B-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNITY, CELLULAR; INJECTIONS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; RUSSIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65149106325     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309102803     Document Type: Article

References (38)

1. Petri M. Clinical features of systemic lupus erythematosus. Curr Opin Rheumatol 1995; 7: 395-401.
2. Worrall JG Snaith ML Batchelor JR Isenberg DA. SLE: A rheumatological view. Analysis of the clinical features, serology and immunogenetics of 100 SLE patients during long-term follow-up. Q J Med 1990; 74: 319-330.
3. Isenberg D Rahman A. Systemic lupus erythematosus-2005 annus mirabilis ? Nat Clin Pract Rheumatol 2006; 2:145-152.
4. Moses N Wiggers J Nicholas C Cockburn J. Prevalence and correlates of perceived unmet needs of people with systemic lupus erythematosus. Patient Educ Couns 2005; 57: 30-38.
5. Kyttaris VC Katsiari CG Juang YT Tsokos GC. New insights into the pathogenesis of systemic lupus erythematosus. Curr Rheumatol Rep 2005; 7: 469-475.
6. Manson JJ Isenberg DA. The pathogenesis of systemic lupus erythematosus. Neth J Med 2003; 61: 343-346.
7. Childs SG. The pathogenesis of systemic lupus erythematosus. Orthop Nurs 2006; 25: 140-145.
8. Mok CC. Emerging drug therapies for systemic lupus erythematosus. Expert Opin Emerg Drugs 2006; 11: 597-608.
9. Eisenberg R Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol 2006; 2: 20-27.
10. Looney RJ Anolik J Sanz I. New therapies for systemic lupus erythematosus: Cellular targets. Rheum Dis Clin North Am 2006; 32: 201-215.
11. Goldblatt F Isenberg DA. New therapies for systemic lupus erythematosus. Clin Exp Immunol 2005; 140: 205-212.
12. Sabahi R Anolik JH. B-cell-targeted therapy for systemic lupus erythematosus. Drugs 2006; 66: 1933-1948.
13. Dorner T. Crossroads of B cell activation in autoimmunity: Rationale of targeting B cells. J Rheumatol Suppl 2006; 77: 3-11.
14. Pugh-Bernard AE Cambier JC. B cell receptor signaling in human systemic lupus erythematosus. Curr Opin Rheumatol 2006; 18: 4510-4515.
15. Dillon SR Gross JA Ansell SM Novak AJ. An APRIL to remember: Novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006; 5: 235-246.
16. Moore PA Belvedere O Orr A. BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-263.
17. Schneider P MacKay F Steiner V. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189: 1747-1756.
18. Gross JA Johnston J Mudri S. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404: 995-999.
19. Mackay F Woodcock SA Lawton P. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190: 1697-1710.
20. Zhang J Roschke V Baker KP. Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6-10.
21. Cheema GS Roschke V Hilbert DM Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44: 1313-1319.
22. Roschke V Sosnovtseva S Ward CD. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002; 169: 4314-4321.
23. Tan SM Xu D Roschke V. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003; 48: 982-992.
24. Groom J Kalled SL Cutler AH. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002; 109: 59-68.
25. Marsters SA Yan M Pitti RM Haas PE Dixit VM Ashkenazi A. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 2000; 10: 785-788.
26. Bossen C Schneider P. BAFF, APRIL and their receptors: Structure, function and signaling. Semin Immunol 2006; 18: 263-275.
27. Thompson JS Bixler SA Qian F. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001; 293: 2108-2111.
28. Hendriks J Planelles L de Jong-Odding J. Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ 2005; 12: 637-648.
29. Ingold K Zumsteg A Tardivel A. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 2005; 201: 1375-1383.
30. Gross JA Dillon SR Mudri S. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity 2001; 15: 289-302.
31. Munafo A Priestley A Nestorov I Visich J Rogge M. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol 2007; 63: 647-656.
32. Tak PP Thurlings RM Rossier C. Atacicept in patients with rheumatoid arthritis: Results of a multicenter, Phase Ib double-blind, placebo-controlled, dose-escalating, single- and repeat-dose study. Arthritis Rheum 2008; 58: 61-72.
33. Tan EM Cohen AS Fries JF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
34. Bombardier C Gladman DD Urowitz MB Caron D Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640.
35. Dall'Era M Chakravarty E Wallace D. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007; 56: 4142-4150.
36. Eisenberg R. Targeting B cells in SLE: The experience with rituximab treatment (anti-CD20). Endocr Metab Immune Disord Drug Targets 2006; 6: 345-350.
37. Dorner T Kaufmann J Wegener WA Teoh N Goldenberg DM Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006; 8: R74.
38. Ding C Jones G. Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline. Curr Opin Investig Drugs 2006; 7: 464-472.